Promethera Biosciences
Mont-saint-guibert
About Promethera Biosciences
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $149.1M
- Funding stage: Late Stage Venture
- Last round: Series D (Dec 2019)
- Website: promethera.com
- Phone: 32 1 039 43 00
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/promethera-biosciences-128785 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.